Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12619000207112
Ethics application status
Approved
Date submitted
23/01/2019
Date registered
13/02/2019
Date last updated
21/07/2020
Date data sharing statement initially provided
13/02/2019
Type of registration
Retrospectively registered
Titles & IDs
Public title
A Longitudinal Cohort Study of ‘Watch and Wait’ in Complete Clinical Responders after Chemo-radiotherapy for Localised Rectal Cancer
Query!
Scientific title
A Longitudinal Cohort Study of ‘Watch and Wait’ in Complete Clinical Responders after Chemo-radiotherapy for Localised Rectal Cancer
Query!
Secondary ID [1]
297185
0
Nil known
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
REctal cancer Non-Operative (RENO)
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Rectal Cancer
311238
0
Query!
Condition category
Condition code
Cancer
309860
309860
0
0
Query!
Bowel - Back passage (rectum) or large bowel (colon)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Patients will complete chemoradiation and then based on response (complete response or other) they will be allocated to one of the two study cohorts; follow up with MRI scans (complete responders -considered the intervention arm) or surgery (other).
The surgery is considered the standard arm.
For patients whom are complete responders and go onto the MRI arm, they will not receive surgery. Instead they will be followed up with clinical assessments and sigmoidoscopy, every 3 months for two years; CT scan at 6, 12 and 24 months; MRI and blood tests every 3 months in the first year then 6 monthly in the second year.
Query!
Intervention code [1]
313444
0
Treatment: Other
Query!
Comparator / control treatment
Patients will complete chemoradiation and then based on response (complete response or other) they will be allocated to one of the two study cohorts; follow up with MRI scans (complete responders) or surgery (other). Surgery is the control and the standard pathway for patients. [Clinical practice guidelines for the prevention, early detection and management of colorectal cancer” developed by Cancer Council Australia,
These guidelines are in line with the available evidence and in keeping with recommendations from international guidelines (ESMO and NCCN)]
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
318804
0
1. Determine the efficacy of the ‘Watch and Wait’ strategy, by measuring the following endpoints:
a. Co-Primary endpoint-1: The ‘two-year local failure rate’ (in the ‘Watch and Wait’ arm) defined as local recurrence that cannot be resected with clear margins - determined by patients through MRI, CT scan and surgical review.
Query!
Assessment method [1]
318804
0
Query!
Timepoint [1]
318804
0
This will be assessed up to two years following chemoradiation using the following
Sigmoidoscopy, every 3 months for two years
CT scan at 6, 12 and 24 months
MRI & blood tests every 3 months in the first year then 6 monthly in the second year
Query!
Primary outcome [2]
318969
0
b. Co-Primary endpoint-2: The rate of rectal preservation (in the ‘Watch and Wait’ arm) measured by number of patients not requiring surgery
Query!
Assessment method [2]
318969
0
Query!
Timepoint [2]
318969
0
Two years post end of patients chemoradiation treatment
Query!
Secondary outcome [1]
366102
0
1. Determine the safety of the ‘Watch & Wait’ strategy by measuring the following endpoint (in the watch and wait arm): (composite)
a. The ‘two-year local recurrence rate’
b. The ‘two-year distant metastasis rate’
c. The overall survival
d. The ‘incurable disease-free survival rate’ (recurrent cancer that cannot be surgically excised with the intention of achieving a cure)
These will be assessed through the use of MRI's, CT scans, sigmoidoscopy and clinical examinations.
Query!
Assessment method [1]
366102
0
Query!
Timepoint [1]
366102
0
This will be assessed up to two years following chemoradiation using the following
Sigmoidoscopy, every 3 months for two years
CT scan at 6, 12 and 24 months
MRI & blood tests every 3 months in the first year then 6 monthly in the second year
Clinic visit every 3 months
Query!
Secondary outcome [2]
366104
0
To investigate Patient reported Outcome Measures -Quality of Life
Quality of Life is defined as the general well-being of the individual; this outcome is measured using the EORTC QLQ-C30 questionnaire which is a validated questionnaire developed to assess the quality of life of cancer patients. The EORTC QLQ-CR-29 will also be used; this is a validated questionnaire developed to assess the quality of life of patients with a history of colorectal cancer and is used in addition to the EORTC QLQ-C30 questionnaire.
Query!
Assessment method [2]
366104
0
Query!
Timepoint [2]
366104
0
Completed in all patients at screening, 6-8 weeks post chemoradiotherapy, 12 months and 24 months post chemoradiotherapy.
Query!
Secondary outcome [3]
366873
0
To investigate Patient reported Outcome Measures - Health Related Quality of Life.
Health-related quality of life is a multi-dimensional concept that includes domains related to physical, mental, emotional and social functioning. This outcome will be measured using a validated questionnaire: the EQ-5D-5L questionnaire
Query!
Assessment method [3]
366873
0
Query!
Timepoint [3]
366873
0
completed in all patients at screening, 6-8 weeks post chemoradiotherapy, 12 months and 24 months post chemoradiotherapy.
Query!
Secondary outcome [4]
366874
0
To investigate Patient reported Outcome Measures - Fear of Cancer Recurrence
Fear of Cancer Recurrence (FCR) defined as feeling anxious about the cancer coming back and is measured by Fear of Cancer Recurrence Inventory (FCRI SF). To interpret the FCR results and to measure response efficacy we will use a modified Response Efficacy Scale specifically designed for this study.
Query!
Assessment method [4]
366874
0
Query!
Timepoint [4]
366874
0
All patients will complete the Fear of Cancer Recurrence Inventory at screening, 6-8 weeks post chemoradiotherapy, 12 months and 24 months post chemoradiotherapy.
The Response efficacy questionnaire will be implemented at 12 and 24 months post chemoradiotherapy.
Query!
Secondary outcome [5]
366875
0
To investigate Patient reported Outcome Measures - survivorship and supportive care needs
Ongoing supportive care needs across the survivorship continuum will be measured using Cancer Survivors unmet needs (CaSUN) questionnaire
Query!
Assessment method [5]
366875
0
Query!
Timepoint [5]
366875
0
This will be measured in all patients at 12 months and 24 months post chemoradiotherapy.
Query!
Secondary outcome [6]
366876
0
To investigate Patient reported Outcome Measures - Bowel Related Quality of Life.
This outcome encompasses multiple aspects of bowel function and will be measured using the MSKCC Bowel Function Questionnaire and LARS score.
Query!
Assessment method [6]
366876
0
Query!
Timepoint [6]
366876
0
All patients will complete the Fear of Cancer Recurrence Inventory at screening, 6-8 weeks post chemoradiotherapy, 12 months and 24 months post chemoradiotherapy.
Query!
Eligibility
Key inclusion criteria
1. Age 18 years or older
2. Biopsy proven locally advanced rectal adenocarcinoma:
o Locally advanced disease defined as: T3 AND N0-2, T1-2 AND N1-2 [Based on AJCC UICC 2017]
3. Subject to undergo Long Course Neoadjuvant Chemo-Radiotherapy based on a multidisciplinary meeting recommendation
4. Considered suitable for long course pelvic radiation therapy
5. Considered suitable for surgery
6. Considered suitable for MRI
7. Willing and able to comply with all study requirements, including treatment and follow up assessments
8. Signed, written informed consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Presence of metastatic disease (M1)
2. T4 disease based on AJCC 2017
3. Local recurrence of previously treated rectal cancer
4. Previous pelvic radiotherapy
5. Contraindication to fluoropyrimidine chemotherapy
6. History of another malignancy:
a. Patients with a past history of adequately treated carcinoma-in-situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or superficial transitional cell carcinoma of the bladder are eligible. Patients with a history of other malignancies are eligible if they have been continuously disease free for at least 5 years after definitive primary treatment.
7. Concurrent illness, including severe infection that may jeopardize the ability of the patient to undergo the chemoradiation with reasonable safety
8. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol including chemoradiation and/or follow-up schedule.
Query!
Study design
Purpose of the study
Educational / counselling / training
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
23/01/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
250
Query!
Accrual to date
1
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA
Query!
Funding & Sponsors
Funding source category [1]
301741
0
Other Collaborative groups
Query!
Name [1]
301741
0
Australian Gastro-intestinal Trials Group
Query!
Address [1]
301741
0
GI Cancer Institute @Lifehouse
Level 6, 119-143 Missenden Rd
Camperdown NSW 2050
Query!
Country [1]
301741
0
Australia
Query!
Primary sponsor type
Government body
Query!
Name
Southern Adelaide Local Health Network Inc
Query!
Address
Flinders Medical Centre
Flinders Drive
Bedford Park
SA 5042
Query!
Country
Australia
Query!
Secondary sponsor category [1]
301482
0
None
Query!
Name [1]
301482
0
Query!
Address [1]
301482
0
Query!
Country [1]
301482
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
302461
0
Southern Adelaide Clinical Human Research Ethics
Query!
Ethics committee address [1]
302461
0
1 Flinders Drive
Bedford park
SA 5042
Query!
Ethics committee country [1]
302461
0
Australia
Query!
Date submitted for ethics approval [1]
302461
0
Query!
Approval date [1]
302461
0
09/10/2018
Query!
Ethics approval number [1]
302461
0
Query!
Summary
Brief summary
The purpose of this study is to determine the effectiveness of a ‘wait and watch’ strategy in patients with rectal cancer who have completed chemoradiotherapy.
Who is it for?
You may be eligible for this study if you are an adult who has been diagnosed with advanced rectal cancer and will be undergoing chemoradiotherapy.
Study details
After chemoradiotherapy you will be reviewed for any evidence of cancer, through physical exams, imaging and sigmoidoscopy. If there is evidence of cancer you will have surgery to remove this cancer. If there is no evidence of cancer you will not have surgery but instead be followed up at set time points over 2 years, having further imaging, physical exams blood tests and sigmoidoscopy's.
it is hoped that this research will provide support for the pathway of not conducting surgery on patients who have no evidence of cancer after their chemoradiotherapy.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
90298
0
Prof Chris Karapetis
Query!
Address
90298
0
Flinders Medical Centre
Flinders Drive
Bedford Park
SA 5042
Query!
Country
90298
0
Australia
Query!
Phone
90298
0
+61 8 82046151
Query!
Fax
90298
0
Query!
Email
90298
0
[email protected]
Query!
Contact person for public queries
Name
90299
0
Miss Dania Ruminski-Smith
Query!
Address
90299
0
Flinders Medical Centre
Flinders Drive
Bedford Park
SA 5042
Query!
Country
90299
0
Australia
Query!
Phone
90299
0
+61 8 8 2047009
Query!
Fax
90299
0
Query!
Email
90299
0
[email protected]
Query!
Contact person for scientific queries
Name
90300
0
Miss Dania Ruminski-Smith
Query!
Address
90300
0
Flinders Medical Centre
Flinders Drive
Bedford Park
SA 5042
Query!
Country
90300
0
Australia
Query!
Phone
90300
0
+61 8 8 2047009
Query!
Fax
90300
0
Query!
Email
90300
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Not in the ethical submission, plan and approval
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Recent Advances and Ongoing Challenges.
2021
https://dx.doi.org/10.1016/j.clcc.2020.12.005
Embase
A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol.
2022
https://dx.doi.org/10.1186/s12885-022-09304-x
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF